
FDA’s Semaglutide Shortage Resolution: Legal Implications and Risks for Compounding Pharmacies
Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide injection products Wegovy and Ozempic (the “February Declaratory Order”). On March 10th, the FDA issued guidance …